LTX-315-enabled, radiotherapy-boosted immunotherapeutic control of breast cancer by NK cells.

ABSTRACT: LTX-315 is a nonameric oncolytic peptide in early clinical development for the treatment of solid malignancies. Preclinical and clinical evidence indicates that the anticancer properties of LTX-315 originate not only from its ability to selectively kill cancer cells, but also from its capacity to promote tumor-targeting immune responses. Here, we investigated the therapeutic activity and immunological correlates of intratumoral LTX-315 administration in three syngeneic mouse models of breast carcinoma, with a focus on the identification of possible combinatorial partners. We found that breast cancer control by LTX-315 is accompanied by a reconfiguration of the immunological tumor microenvironment that supports the activation of anticancer immunity and can be boosted by radiation therapy. M

SUBMITTER: Yamazaki T 

PROVIDER: S-EPMC8366543 | biostudies-literature | 2021

REPOSITORIES: biostudies-literature